Yael Kenan
Prior to joining Transpharma, Dr. Kenan was responsible for Global Clinical Drug Development in the field of Parkinson disease at Teva Pharmaceutical Industries. She brings to TransPharma extensive industry experience. In her position at Teva, she was responsible for planning and managing clinical development plans (phase I to III) of new anti-Parkinson drugs and took a leading role in receiving the global marketing authorization of Teva’s second innovative drug, Azilect. Dr. Kenan holds a Ph.D. in biochemistry from the Hebrew University of Jerusalem and an MBA from the Technion-Israel Institute of Technology. She was also a research fellow at the US National Institute of Health.
Affiliated Companies
Additional Information
No additional information has been added yet. Add a LinkedIn URL.
Invested In
No investments.